

Growing
a **New Future**

Investor
Presentation



GREENKOM
GROUP

Disclaimer

This presentation was prepared by Greenkom Group (hereinafter: "the company").

This presentation should not be considered as an opinion, proposal, recommendation, or advice/marketing to purchase and/or hold and/or sell securities of the company, and the presentation does not replace individually tailored investment advice/marketing or pension advice/marketing that considers a person's individual needs and circumstances. This presentation is intended solely for the purpose of delivering and presenting information and does not constitute a substitute for reports periodically published by the company to the public, as part of its legal obligations.

The content in this presentation is solely the view of its authors and reflects their understanding at the time of its presentation.

The information, details, and analysis in the presentation, including the opinions presented therein, may change at any time, and without any notification on the part of the company.

Different subjects included in this presentation, including forecasts, objectives, evaluations, estimations, and other information pertaining to future events and/or matters, the realization of which is uncertain and not subject to the company's control, including in relation to forecasts of income and profitability, is forward-looking information, as defined in the Securities Law-1968, and is based on the company management's subjective estimations made according to data and information known to the company when preparing the presentation.

The realization or non-realization of the forward-looking information will be influenced, among others, by risk factors that characterize the company's activity, and by general developments and external factors that influence the company's activity, which cannot be estimated in advance and that are not subject to the company's control. The results of the company's activity may be materially different from estimated results or from those understood from the presentation. Readers of the presentation are therefore hereby warned that the actual future results and achievements of the company may differ materially from those presented in the forward-looking information included in this presentation.

Who are we?



« Growing Medical Cannabis

Since its inception in July 2017, the company has been active in growing and breeding medical cannabis and medical cannabis-based products, while initiating collaborations with other local and foreign companies.

« Smart Growing Farm with Advanced Automation Capabilities


The smart growing farm at Kfar Achim includes an area of 10,000 m² with greenhouses that operate on an area of 4,500 m², plant breeding on an area of 1,500 m², and a further 4,000 m² that are used for the company's offices and a post-harvest facility that includes a safe and rooms for drying, aging, processing, and trimming.

« Widespread R&D Activity

The company engages in unique R&D in the growing and enhancing of specially designated species of cannabis with a medical connection. The company owns hundreds of dunams and has, thus far, developed more than 28 commercial species, 2 of which have been sold to customers.

« Consultation

Although still new, the farm provides consultation and guidance services for a variety of farms in Israel currently constructing greenhouses and post-harvest facilities and economizing the farm's operation and maintenance.



The Company's Vision

To be a leading innovative cannabis group with a global brand, capable of supplying the entire value chain in the growing and distribution of medical cannabis products



The Medical Cannabis Market in Israel

« A constant increase in the number of patients

Average yearly growth of **37%** in the number of patients treated with medical cannabis between 2014-2020. An increase of **45%** in 2020.

« Growth from different directions



An average of approx. **2,300** new patients every month during the last year. An average growth of **5%** in the quantity of cannabis consumed per user during the last year.

« Growth trends that will be sustained in the future


The market is expected to continue displaying strong growth in the years to come due to a decline in the cost of issuing a license and an increase in the number of doctors entitled to issue licenses.

« Legalization

Opening the market, as in many countries worldwide (New York authorized legalization in March 2021) will lead to an estimated **ten-fold** increase compared to today.



Number of Medical Cannabis Patients in Israel (thousands)



The Global Medical Cannabis Market

« Trends supporting growth in the global cannabis market

- ◁ Regulatory changes and extensive legalization of medical cannabis (more than 40 countries)
- ◁ Expanded medical applications of cannabis
- ◁ Increased awareness of the uses of medical cannabis
- ◁ Increasing demand for medical cannabis during COVID pandemic
- ◁ The State of New York authorized legalization of the cannabis market in March 2021




29%

Expected yearly growth
between 2020-2027

147 billion USD


Expected scope of global
medical cannabis market in
2027

Projected sales of medical cannabis in Europe



Source: Prohibition Partners/Atalis


Structure of Holdings



(*) Rights to 21% of the profits

Production Chain

A Holistic Approach – Presence and Control at Each Stage of the Value Chain



* An agreement has been signed with a pharmacy in southern Israel to directly distribute and sell cannabis products

Milestones



Growing Farm

- « One of the world's most advanced facilities for growing cannabis, integrating numerous automation procedures

Growing at the farm began in February 2020 and 1.2 tons of dry medical cannabis produce has been grown to date. The company expects to end 2021 with 3.5 growing cycles and reach an output of 1.5 tons of medical cannabis.

- « Dynamic growing methods adapted to Indoor and Greenhouse crops

IP for growing and precise post-harvest process for each commercial species that is adapted to the different seasons of the year. The company has 2 experimental Indoor facilities in which different studies are conducted and is currently establishing a 300 m² Indoor growing facility, one of the most advanced of its kind, that is expected to produce 3-4 times more inflorescence than greenhouse crops.

- « Compliance with the stringent IMC-GAP and GACP standards



Laboratory and Genetics

« Extensive R&D activity

The company operates a lab and experimental growing facilities which analyze the plant's components and active substances to identify new medical indications and that perform tests via various extraction methods and cross-breeding of different species.


« The genetic bank

The company has a rich genetic bank with more than 1,000 different species lines imported to Israel and that are characterized by a high THC/CBD/CBG. The company holds the rights to import genetics from the world's leading companies.

« Species development

The company has developed and grafted 28 commercial species adapted to the market of patients suffering from pain.

The company has sold 2 such species developed in 2020 to customers.



Expansion plans

« 17,000 m² added growing area, 8 tons a year added output

In addition to the existing farm, the company plans to build another farm that will include:

- ◀ 9,000 m² growing area
- ◀ 3,000 m² breeding area
- ◀ 2,000 m² Indoor farm
- ◀ 3,000 m² service areas

« Production, Aging, and Oils Factory, and Packaging

- ◀ Construction of a factory on an area of 500 m² near the existing farm.
- ◀ The factory will be constructed based on the most stringent EU-GMP standards of the EU.
- ◀ Export of produce that is compliant with the EU-GMP standard.
- ◀ The company has developed a unique IP for the oil extraction process. Local and global marketing
- ◀ Marketing and distribution in Israel will enable the company to produce diverse cannabis products. The company will hold licenses to distribute them to pharmacies and the end consumer.
- ◀ Strengthening of the company's presence at each stage of the Israeli cannabis world's value chain.



Export and Global Activity



The company has established collaborations and strong relations with cannabis companies worldwide



« Collaboration with a global agriculture company located in Abu Dhabi. As part of the memorandum of understanding signed between the two companies, the company from Abu Dhabi is investing all the capital in the joint ventures and Greenkom brings the knowledge, species, and regulatory expertise. Profits from the joint venture will be divided equally between the parties.



« Collaboration with an international cannabis company located in the Netherlands. The company is a world leader and known for its unique species that are marketed in the US and Europe. A memorandum of understanding is currently being signed.

- ◀ Representation of the company in Israel
- ◀ Importing and selling new species
- ◀ Establishment of a joint distribution network
- ◀ Marketing of Greenkom's species via the international network



Greenkom - Relative advantages

« One of the most advanced cannabis growing facilities

A facility characterized by compliance with the stringent GACP and IMC-GAP criteria and a dynamic growing method adapted to Greenhouse/Indoor crops. The facility employs advanced technologies that control the different growing processes automatically without human contact.

« Growing methods protected with IP

An IP for the growing process (including fertilizers and treatment of plants) / precise post harvest procedures for each commercial species adapted to the seasons of the year. The growing method ensures fixed reproducibility in the percentage of cannabinoids, terpenes, and flavonoids and the visibility of the inflorescence throughout the year.

« R&D and Genetic Bank

The company operates a laboratory and experimental growing facilities, receives the various genetics, and breaks down the (cannabinoid family) plant components. In addition, the company performs cross-breeding of original species, plant and medical experiments, and has developed dozens of new commercial species.



« Indoor Crops

Experimental Indoor facilities for studies on:

- ◁ Variable/Fixed spectrum, airflow, adjustment of lighting intensity for plant cultivation at an optimal energy level

« Collaborations

Partner in the Shafir Farm with rights to 21% of the profits (without investment on the part of the company)

- ◁ Partnership with Kibbutz Kinneret – presently being finalized
- ◁ Investments in Indoor by a third party
- ◁ International collaborations

Summary

- « Strong and significant presence along the entire value chain
- « Human capital with extensive industry experience
- « Advanced and innovative R&D with unique species developed by the company
- « Capable of selling to pharmacies, end consumers, and pharma companies
- « Extensive regulatory experience and ability to establish connections with diverse entities in Israel and worldwide



Thank You

GREENKOM
GROUP

GREENKOM
LABS

GREENKOM
AGRO

GREENKOM
TECH

GREENKOM
2U

michael@kgroup.co.il
www.kgroup.co.il

